Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in China for malignant ascites

Image: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in China for malignant ascites. Photo: courtesy of fernando zhiminaicela from Pixabay.